Regeneron Pharmaceuticals Inc (REGN) Financials
Key financial figures for Regeneron Pharmaceuticals Inc (Q2 2026).
Regeneron reported Q2 2026 total revenues of $4,291 million (up 17% year over year), GAAP diluted EPS of $12.23, and non-GAAP diluted EPS of $14.29, led by record Dupixent and EYLEA HD sales. Total revenues grew 17% year over year to $4,291 million, driven by higher Dupixent and Libtayo collaboration revenue. Dupixent global net sales (recorded by Sanofi) rose 38% to a record $5,998.2 million; the FDA and European Commission approved Dupixent for chronic spontaneous urticaria (CSU) in April 2026. Combined EYLEA franchise U.S. net sales fell 12% to $1,008 million: EYLEA HD U.S. sales grew 52% to a record $596 million, but older-formulation EYLEA U.S. sales declined 45% to $412 million; the FDA also approved extending EYLEA HD dosing intervals up to every 20 weeks. On the outlook: Updated full-year 2026 guidance: non-GAAP R&D expense $5.950-$6.050 billion, non-GAAP SG&A expense $2.500-$2.600 billion, GAAP gross margin on net product sales 78%-79%, non-GAAP gross margin on net product sales 84%-85%, and capital expenditures $1.030-$1.100 billion. Figures are for Q2 2026, as Regeneron Pharmaceuticals, Inc. reported them.
- Revenue
- $4.3B
- Net Income
- $1.3B
- EPS
- $12.62
- Total Assets
- $41.7B
- Operating Cash Flow
- $813M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $4.3B | $1.3B | $12.20 | 33.11% | $334M |
| Q1 FY2026 | $3.6B | $727M | $6.75 | 17.83% | $848M |
| Q4 FY2025 | $3.9B | $845M | $7.86 | 22.65% | $922M |
| Q3 FY2025 | $3.8B | $1.5B | $13.62 | 27.35% | $1.4B |
| Q2 FY2025 | $3.7B | $1.4B | $12.81 | 29.37% | $968M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $14.3B | $4.5B | $41.48 | 24.95% | $4.1B |
| FY2024 | $14.2B | $4.4B | $38.34 | 28.1% | $3.7B |
| FY2023 | $13.1B | $4.0B | $34.77 | 33.15% | $3.7B |
Frequently asked questions
What was Regeneron Pharmaceuticals, Inc.'s revenue last quarter?
Regeneron Pharmaceuticals, Inc. reported revenue of $4.29 billion for Q2 FY2026, up 16.7% from the same period a year earlier.
Is Regeneron Pharmaceuticals, Inc. profitable?
Yes. Regeneron Pharmaceuticals, Inc. reported net income of $1.30 billion for Q2 FY2026, a net margin of 30.23% on revenue.
How has Regeneron Pharmaceuticals, Inc.'s margin trended?
Operating margin was 33.11% in Q2 FY2026, compared with 29.37% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Regeneron Pharmaceuticals, Inc. generate?
Regeneron Pharmaceuticals, Inc. generated free cash flow of $334.3 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Regeneron Pharmaceuticals Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.